---
title: "Becton, Dickinson and Company (BDX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BDX.US.md"
symbol: "BDX.US"
name: "Becton, Dickinson and Company"
industry: "Health Care Equipment"
datetime: "2026-05-20T10:33:28.387Z"
locales:
  - [en](https://longbridge.com/en/quote/BDX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BDX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BDX.US.md)
---

# Becton, Dickinson and Company (BDX.US)

## Company Overview

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.bd.com](https://www.bd.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: C (0.43)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 48 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.52% |  |
| Net Profit YoY | -23.97% |  |
| P/B Ratio | 1.68 |  |
| Dividend Ratio | 2.84% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 40490665747.65 |  |
| Revenue | 22227000000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.67% | C |
| Profit Margin | 5.12% | C |
| Gross Margin | 45.69% | B |
| Revenue YoY | 15.52% | B |
| Net Profit YoY | -23.97% | D |
| Total Assets YoY | -6.67% | D |
| Net Assets YoY | -4.39% | D |
| Cash Flow Margin | 336.08% | A |
| OCF YoY | 15.52% | B |
| Turnover | 0.42 | C |
| Gearing Ratio | 52.52% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Becton, Dickinson and Company",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "15.52%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-23.97%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.68",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.84%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "40490665747.65",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "22227000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.67%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "5.12%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "45.69%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "15.52%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-23.97%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.67%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-4.39%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "336.08%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "15.52%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.42",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "52.52%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 35.55 | 33/183 | 34.59 | 33.30 | 28.63 |
| PB | 1.68 | 48/183 | 2.19 | 2.06 | 1.88 |
| PS (TTM) | 1.82 | 49/183 | 2.57 | 2.47 | 2.17 |
| Dividend Yield | 2.84% | 5/183 | 2.55% | 2.25% | 2.13% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **16**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 38% |
| Overweight | 1 | 6% |
| Hold | 9 | 56% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 146.95 |
| Highest Target | 225.00 |
| Lowest Target | 157.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BDX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BDX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BDX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BDX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**